Observational studyOphthalmology2023
Validation of Rates of Mean Deviation Change as Clinically Relevant End Points for Glaucoma Progression.
Observational study in Ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Risk stratification of visual field progression in optic disc drusen with and without glaucoma.International ophthalmology · 2026Article
- The Efficacy of Nicotinamide in Maintaining Mean Deviation in Glaucoma: A Systematic Review.Cureus · 2026Review
- An Artificial Intelligence-Based Prognostic Model for Prediction of Functional Glaucoma Progression From Clinical and Structural Data.American journal of ophthalmology · 2026Article
- Surgical Interventions in Idiopathic Intracranial Hypertension-A Comprehensive Multi-Center Study of Outcome and the Role of Treatment Indication.European journal of neurology · 2026Observational
- Visual Field Progression in Childhood Glaucoma Versus Open-Angle Glaucoma: A Retrospective Comparative Study.Journal of clinical medicine · 2026Article
- Initial circumpapillary retinal nerve fibre layer rates of change predict glaucomatous progression.Eye (London, England) · 2025Article
- Detection of glaucoma progression on longitudinal series of en-face macular optical coherence tomography angiography images with a deep learning model.The British journal of ophthalmology · 2024Observational
- Prediction of visual field progression with serial optic disc photographs using deep learning.The British journal of ophthalmology · 2024Article
- Prediction of Visual Field Progression with Baseline and Longitudinal Structural Measurements Using Deep Learning.American journal of ophthalmology · 2024Article
- Short-term Detection of Fast Progressors in Glaucoma: The Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study.Ophthalmology · 2024Article
- Estimating the Distribution of True Rates of Visual Field Progression in Glaucoma.Translational vision science & technology · 2024Article
- Mapping vision loss of patients in a glaucoma backlog following the COVID-19 pandemic: a real-world analysis using the Glauc-Strat-Fast risk stratification tool.Eye (London, England) · 2024Article
- Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma.Translational vision science & technology · 2023Article
- Short-Term Rates of Visual Field Change Predict Glaucoma Progression.Ophthalmology. GlaucomaObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeTo investigate whether rates of standard automated perimetry (SAP) mean deviation (MD) over an initial 2-year follow-up period were predictive of events of visual field progression over an extended follow-up.
designLongitudinal, prospective, observational study.
participantsTwo hundred forty-six eyes of 168 patients with glaucoma followed up every 6 months for up to 5 years.
methodsPatients were required to have a minimum of 5 reliable SAP tests during the first 2 years of follow-up. Events of progression were evaluated using 2 methods: Guided Progression Analysis (GPA; Carl Zeiss Meditec, Inc) and a United States Food and Drug Administration (FDA)-suggested end point. The date of the first test showing progression after the first 2 years was considered to be the event date. Rates of change in SAP MD were calculated for the first 2 years of follow-up, and joint longitudinal survival models were used to assess the risk of faster initial MD loss for subsequent progression based on each event analysis.
main outcome measureRisk of having an event of progression based on initial rates of SAP MD change.
resultsFifty-six eye (22.8%) showed an event of progression by the GPA and 51 eyes (20.7%) did so by the FDA end point. Each 0.1-dB/year faster rate of SAP MD loss in the first 2 years was associated with a 26% increase in risk of a GPA progression end point developing (R
conclusionsRates of SAP MD change for eyes with glaucoma calculated over the initial 2 years of follow-up were strongly predictive of events of progression over subsequent follow-up. Our findings give support for the use of slopes of MD change as suitable end points of progression in clinical trials. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.